Determinants of Physical Activity among Middle School Girl Students in Iran Based on Social Cognitive Theory in 2018

Introduction: Physical activity is one of the most fundamental health promoting behaviors influenced by behavioral, environmental and individual determinants. The present study was conducted to determine the factors affecting physical activity among middle school girl students based on social cognitive theory in Rafsanjan city in 2018. The present cross-sectional study was carried out among 325 middle school girl students through multi-stage sampling; required data was collected using a questionnaire containing three sections of demographic characteristics, standard questionnaire of physical activity assessment during the last week and a questionnaire based on the constructs of cognitive social theory; questionnaires were completed through self-report and analyzed at the significance level of 0/05 by SPSS-16 using relevant statistical tests. The mean daily physical activity of students was 24.14 ± 26.42 minutes. Spearman correlation test showed a positive and significant relationship between daily physical activity of students with environmental factors, knowledge, behavioral skills, outcome expectation, outcome value, family support, friends support and self-efficacy of students (P<0.05). Self-efficacy was the strongest predictor of behavior among the structures of the theory. Considering the unfavorable state of physical activity and the results of research, it is highly recommended to design, implement and evaluate interventions based on social cognitive theory in different target groups affecting adolescents (family and friends) in order to increase the physical activity of girl students. &nbsp

Comparing pili producing gene (mtp-flp) in susceptible and resistant dormant Mycobacterium tuberculosis strains with active clinical isolates

Background: Pili producing genes in different life cycles of Mycobacterium tuberculosis (M. tuberculosis) were assessed. M. tuberculosis has two life cycles: dormant and active states. We aimed to assess the pili producing genes such as curli pili of M. tuberculosis (mtp) encoded by the mtp gene (Rv3312A) and fimbrial low-molecular-weight protein encoded by flp gene (Rv3656c) which were compared and analyzed. Methods: Two hundred M. tuberculosis isolates were investigated both at active and dormant states for production and expression of pili. The dormant M. tuberculosis was achieved by incubation in a sealed tube (modified Wayne method). The susceptibility of M. tuberculosis was evaluated on genes, rpob, inh, katg, and gyra by using multiplex polymerase chain reaction (PCR) and single-strand conformational polymorphism methods. The PCR–restriction fragment length polymorphism was used to express pili genes mtp and flp and then the PCR products was digested using restriction enzyme Fnu4HI, XmaI, and MspJI and AciI, TagII, and HaeII, respectively. The transmission electron microscopy was also used to detect pili in different isolates. The result was compared and analyzed using H37RV as a gold standard. Results: The mtp and flp PCR products were 263 and 122 bp in the studied strains irrespective of M. tuberculosis different life cycles, respectively. The PCR products were analyzed on 8% Polyacrylamide gel electrophoresis (PAGE), and in the 180/200 (20%), producing five fragments of 25,40,45,63,90 bp with the Fun4HI and two fragments of 126,138 bp with the XmaI and uncut with the MspJI for mtp gen were obtained at the dormant and active states of M. tuberculosis (P 0.05). Conclusion: Pili were shown by electron microscopy, although at the gene expression, the insignificant difference was observed at the dormant strains in comparison to active states. Therefore, we may conclude that other genes might be involved in pili production of M. tuberculosis that needs further investigation. Although, the resistance phenomena might influence the pili producing gene expression that showed in our results

Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review

Abstract Background Remdesivir is being studied and used to treat coronavirus disease 2019 (COVID-19). This study aimed to systematically identify, critically evaluate, and summarize the findings of the studies on the cost-effectiveness of remdesivir in the treatment of hospitalized patients with COVID-19. Methods In this systematic review, PubMed, EMBASE, Web of Science, SCOPUS, and the Cochrane Library were searched for studies published between 2019 and 2022. We included all full economic evaluations of remdesivir for the treatment of hospitalized patients with COVID-19. Data were summarized in a structured and narrative manner. Results Out of 616 articles obtained in this literature search, 12 studies were included in the final analysis. The mean score of the Quality of Health Economic Studies (QHES) for the studies was 87.66 (high quality). All studies were conducted in high-income countries (eight studies in the USA and one study in England), except for three studies from middle-to-high-income countries (China, South Africa, and Turkey). Six studies conducted their economic analysis in terms of a health system perspective; five studies conducted their economic analysis from a payer perspective; three studies from the perspective of a health care provider. The results of five studies showed that remdesivir was cost-effective compared to standard treatment. Furthermore, the therapeutic strategy of combining remdesivir with baricitinib was cost-effective compared to remdesivir alone. Conclusions Based on the results of the present study, remdesivir appears to be cost-effective in comparison with the standard of care in China, Turkey, and South Africa. Studies conducted in the United States show conflicting results, and combining remdesivir with baricitinib is cost-effective compared with remdesivir alone. However, the cost-effectiveness of remdesivir in low-income countries remains unknown. Thus, more studies in different countries are required to determine the cost-effectiveness of this drug